Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Poly(ADP-ribose) polymerase-1 (PARP-1) is crucial for genomic integrity and DNA repair.
• PARP-1 inhibition is a potential cancer therapy, but current inhibitors may cause off-target effects.
• Selective PARP-1 inhibition is needed to improve cancer treatment efficacy and safety.

Purpose of the Study:

• To investigate allosteric regulation of PARP-1 as a strategy for selective inhibition.
• To assess the impact of disrupting PARP-1 domain-domain contacts on its function.
• To evaluate the potential of selective PARP-1 inhibition in combination with chemotherapy.

Main Methods:

• Mutagenesis to disrupt PARP-1 domain-domain contacts.
• Assessing PARP-1 recruitment to DNA damage sites and transcriptional regulation.
• Evaluating catalytic activation of PARP-1 mutants.
• Overexpressing PARP-1 mutants in pancreatic cancer cells (MIA PaCa-2) and assessing sensitivity to platinum-based agents.
• Development of a high-throughput PARP-1 assay.

Main Results:

• Disruption of PARP-1 domain contacts did not affect recruitment to DNA damage or transcription.
• Mutagenesis prevented DNA-damage-dependent catalytic activation of PARP-1.
• Overexpression of PARP-1 mutants increased sensitivity to platinum-based chemotherapy in pancreatic cancer cells.
• A high-throughput assay for PARP-1 was developed.

Conclusions:

• Allosteric regulation of PARP-1 is a viable strategy for selective inhibition.
• Targeting PARP-1 allosterically can enhance the efficacy of DNA-damaging agents in cancer therapy.
• Selective PARP-1 inhibition holds promise for treating genomically unstable cancers.
• The developed assay will facilitate the discovery of novel PARP-1 selective inhibitors.